Premium
Non‐alcoholic fatty liver disease patients attending two metropolitan hospitals in Melbourne, Australia: high risk status and low prevalence
Author(s) -
George Elena S.,
Roberts Stuart K.,
Nicoll Amanda J.,
Reddy Anjana,
Paris Tonya,
Itsiopoulos Catherine,
Tierney Audrey C.
Publication year - 2018
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13973
Subject(s) - medicine , fatty liver , asymptomatic , gastroenterology , body mass index , cirrhosis , liver disease , diabetes mellitus , transient elastography , alcoholic liver disease , disease , endocrinology , liver fibrosis
Background Non‐alcoholic fatty liver disease (NAFLD) is the most common liver disease globally, with increased rates in high‐risk populations, including type 2 diabetes and obesity. The condition increases the risk of end‐stage liver disease, hepatocellular carcinoma and all‐cause mortality. NAFLD is asymptomatic and often remains undiagnosed as routine screening in high‐risk groups is not practised. Aims The aim of this study was to determine the rates and characteristics of NAFLD patients attending liver clinics at two Melbourne metropolitan hospitals. Methods Liver clinics were prospectively screened for 10 consecutive months and participants with a diagnosis of NAFLD were further evaluated using pathology and imaging results obtained from medical records. Results Of the 2050 patients screened, 148 (7%) had NAFLD predominantly diagnosed using ultrasound (81%). NAFLD patients were obese (mean body mass index 30.7 ± 5.9 kg/m 2 ), insulin resistant (median HOMA 4.2 (3.2) mmol/L) and had elevated liver enzymes (ALT median, males 47.0 (34.3), females 36.0 (28.0) U/L), and 18% of patients had liver stiffness measuring >12 kPa, suggesting a moderate probability of cirrhosis. Patients with liver stiffness measuring ≥9.6 kPa had significantly higher: glucose (median 5.5 (1.2) vs 6.2 (5.3) mmol/L, P = 0.007), aspartate aminotransferase levels (median 25.5 (26.0) vs 41.0 (62.0) u/L, P = 0.0005) and HOMA (3.1 (3.0) vs 5.4 (5.5) mmol/L, P = 0.040). Conclusions NAFLD constituted a minority of liver clinic patients, most of who were obese, insulin resistant and hypertensive, and many had an elevated liver stiffness measurement. NAFLD poses added adverse health outcomes to high‐risk patients, and therefore, early detection is warranted.